The growth and metastasis of solid tumors relies on the activities of polypeptide growth factors to recruit stromal tissue and expand the tumor mass. Pleiotrophin (PTN) is a secreted growth factor with angiogenic activity that has been found to contribute to the growth and metastasis of tumors including melanoma. Here, we present a gene therapy approach of targeting PTN in established tumors using ribozymes. Tetracycline-regulated ribozyme expression vectors were used to deplete conditionally PTN mRNA from melanoma xenograft tumors in vivo. We found that tetracycline-mediated initiation of ribozyme expression in established tumors reduced further tumor growth. Next, we generated synthetic anti-PTN ribozymes that inhibit PTNdependent colony formation of cells in soft agar. Intraperitoneal administration of these synthetic ribozymes into nude mice inhibited growth of PTN-positive, subcutaneous melanoma. Furthermore, PTN released from the tumors into the circulation of mice was reduced after ribozyme treatment. These data show that ribozyme targeting of rate-limiting tumor growth factors could provide an efficient tool for cancer therapy and that the efficacy may be reflected in the reduction of the serum levels of the targeted protein, PTN. Gene Therapy (2005) 12, 339-346.
Introduction
Polypeptide growth factors have been shown to be essential for the growth and metastasis of solid tumors. One of their pivotal roles during tumor progression is to function as autocrine and paracrine stimulators of tumor cells and recruit stromal tissue and blood supply to the expanding tumor mass by inducing angiogenesis. [1] [2] [3] The heparin-binding growth factor pleiotrophin (PTN) is an 18-kDa protein, which was originally purified from the bovine uterus, 4 neonatal rat brain 5, 6 as well as human breast cancer cells. 7 PTN is expressed in normal developing tissues, including the embryonic brain, uterus and placental tissue, but not in normal endothelial cells, melanocytes or fibroblasts. [4] [5] [6] [8] [9] [10] [11] In situ hybridization studies in rodents 12, 13 demonstrated that the gene is highly expressed in the neuroepithelium and ependyma during the second half of intrauterine development and, to a lower extent, is also detected in the lung, reproductive tract, gastrointestinal tract, kidney and bone. With progressing organ differentiation, PTN gene expression is increasingly restricted to a few sites and drops sharply after the perinatal phase. In the adult, only few structures such as the hippocampal region and cerebral cortex show very low but detectable levels of PTN gene expression. 13, 14 In tumors, PTN was first purified from the supernatants of MDA-MB231 human breast cancer cells. 7 High levels of PTN gene expression were found in a variety of established tumor cell lines and primary human tumor specimens. We found the highest levels of PTN expression in tumors originating from neuroectodermal cell lineages, that is, in human melanoma and glioblastoma multiforme tissues and in cell lines derived from these malignant lesions. 8 Interestingly, the receptor for PTN as well as the related growth factor midkine, anaplastic lymphoma kinase (ALK 15, 16 ), also showed very high expression levels in neuroectodermal tumors or cell lines and was rate-limiting for their growth in vitro and in vivo. 17 PTN is mitogenic for fibroblasts and endothelial cells, 8, 18, 19 induces tube formation of endothelial cells and angiogenesis, 20 has transforming activity on epithelial cells 7, 21 and fibroblasts, 4, 6, 22 and can induce neurite outgrowth. 5, 6 Finally, PTN is a survival factor for fibroblasts and epithelial cells. 18 The role of PTN during tumor growth is suggested by studies in which overexpression of PTN in SW13 cells 8 and in NIH3T3 fibroblasts 23 supported tumor growth of these nontumorigenic cells in athymic nude mice.
We reported earlier that PTN plays an essential role for the growth, angiogenesis and metastasis of human melanoma in vivo. 24 We showed that proliferative, angiogenic and tumorigenic effects of PTN can be suppressed specifically by hammerhead ribozymes that were designed to cleave PTN mRNA [24] [25] [26] [27] [28] [29] (reviewed in Czubayko et al 30 ). In these studies, we utilized expression vectors with anti-PTN ribozymes driven by a strong viral promoter to reduce the endogenous PTN in tumor cells. Tumor growth in animals as well as their metastatic spread was reduced in parallel with the reduction of the endogenous PTN. 24 These findings are supported by work in the laboratory of M Herlyn, who used virally based expression vectors and showed an impact of PTN on distinct growth phenotypes of melanoma cells. 31 The goals of the present studies were (i) to test whether ribozyme targeting of PTN would be effective after tumors had been established and (ii) to determine the efficacy of exogenously administered synthetic ribozymes to assess the potential utility of ribozymes as anticancer drugs
To approach the first goal, a tetracycline-regulated expression system 32, 33 was utilized to control the expression of PTN-targeted ribozymes and hence, the levels of endogenous PTN in the tumor cells. The system used here allows to switch on gene expression by removal of tetracycline. We show that induction of PTN ribozyme expression leads to reduced tumor growth in vivo. To approach the second goal, one of the prerequisites was to develop synthetic ribozymes that are protected from degradation by omnipresent ribonucleases. For that reason, synthetic DNA/RNA chimeric ribozymes were developed with further chemical modifications to increase nuclease resistance. 24, 34 We demonstrate that systemic (intraperitoneal or intravenous) administration of synthetic ribozymes provides a similar in vivo effect as inducible ribozyme expression in tumor cells, supporting the efficacy of synthetic ribozymes for therapeutic targeting when used as an exogenously administered drug.
Results

Tetracycline-regulated anti-PTN ribozymes
In the first series of experiments, we established tetracycline-regulated, PTN-targeted ribozymes that would ultimately allow for a conditional depletion of the endogenous PTN mRNA in xenograft tumors growing in mice. In this approach, the activity of a tetracycline-response element (TRE) containing promoter is activated by expression of the tetracycline-regulated transactivator protein (tTA). 33 The addition of tetracycline suppresses the activity of tTA. As a model cell line, we chose to use 1205LU human melanoma cells, which depend on PTN for their tumor growth in vivo. 24 A transiently transfected TRE-promoter/luciferase reporter construct 35 showed low background activity and strong induction by co-expression of tTA in the 1205LU cells ( Figure 1 ; lane 1 versus lane 2). The addition of tetracycline suppressed luciferase activity to background levels ( Figure 1 ; lane 2 versus lane 3). Next, 1205LU cells were stably transfected with a TRE-anti-PTN ribozyme construct (Rz66) and cultured in the presence or absence of tetracycline. Northern analysis showed that PTN mRNA levels were reduced by approximately 70% in the absence of tetracycline as compared to cells in the presence of tetracycline (Figure 2 ).
Impact of conditional depletion of PTN on tumor growth
We used this cell system to assess the in vivo efficacy of ribozyme activation on the growth of established tumors. For this, melanoma cells were injected subcutaneously and xenografts were allowed to grow for 7 days in the presence of implanted tetracycline pellets (Figure 3 ). After that, tetracycline pellets were removed in a subset of animals to induce the ribozyme expression. We observed that tumor growth was significantly delayed after tetracycline removal relative to the control group (Po0.05) or tumors growing from wild-type 1205LU cells (Po0.001). No difference in tumor growth was 34 (see Figure 4) . As a proof of principle, we first tested the ability of the synthetic ribozymes created to impact on PTN-dependent growth in vitro. For this, we used SW13 cells that were transfected with PTN and form colonies in soft agar due to PTN expression. 8 This cell system had been established earlier and was successfully used to demonstrate the efficacy and selectivity of PTN-targeted ribozyme expression vectors. 25 Colony formation of SW13/PTN cells occurs in the presence of 10% serum and is observed over a time period of over a week, thus providing a significant challenge to the stability and functionality of the synthetic ribozymes. We found that colony formation of the cells was inhibited in a concentration-dependent manner by treatment with the PTN-targeted synthetic ribozyme. At concentrations of 4100 nM, colony formation was reduced to background levels ( Figure 5a ). To assess the contribution of the catalytic activity versus the antisense effect of the ribozyme, we also used an inactive ribozyme with a point mutation in the catalytic center. This ribozyme will still hybridize with the PTN mRNA but has greatly attenuated catalytic activity. Interestingly, this inactive ribozyme barely reduced colony formation at high concentrations of 400 nM (see Figure 5a ), supporting the notion that the antisense effect is negligible. This finding corroborates our earlier studies demonstrating that enzymatically inactive ribozymes contained in expression vectors had hardly any role in reducing PTN activity in intact cells. 25 As an additional control, we used synthetic ribozymes with an active catalytic center, but Figure 3 In vivo effect of tetracycline-regulated anti-PTN ribozymes on subcutaneous tumor growth. One million stably transfected 1205LU/ tetRz66 melanoma cells were injected subcutaneously into two sites on the flanks of athymic nude mice (5 mice/group) carrying tetracycline pellets that release 0.7 mg tetracycline per day over a period of 60 days. The tetracycline pellets were removed after 7 days (Àtet, open circles) or left till the end of the study (+tet, closed circles). In addition to these two groups, one million wild-type 1205LU cells were injected into two sites in five animals without tetracycline pellets. Depicted are tumor sizes, estimated from the product of the perpendicular diameters of the tumors (mean7 s.e.m.; *Po0.05 Àtet versus +tet and Po0.001 Àtet versus wild type). Ribozyme targeting of PTN in tumors C Malerczyk et al with a nonspecific targeting sequence, to rule out effects due to the enzymatic activity of the ribozyme. This ribozyme also did not show any effect on colony formation of the SW13/PTN cells at a concentration of 400 nM. From this series of studies, we concluded that the synthetic ribozyme design can provide a stable and functional reagent with which we would be able to inhibit the PTN effect on cell growth.
Effect of PTN-targeted synthetic ribozymes on tumor growth, metastasis and serum levels of PTN Growth of subcutaneous tumors. In a first in vivo study, treatment of animals with a combination of PTNtargeted (Rz66 and Rz261) was compared to that with nonspecific, synthetic ribozymes. Tumor xenografts from the 1205LU human melanoma cells were grown subcutaneously in athymic nude mice for 9 days and then the tumor-bearing nude mice received synthetic ribozymes intravenously every third day for a period of another 10 days. For this route of administration, we used 'naked' ribozymes rather than a complex with liposomes or cationic lipids, as it had been shown that this formulation can be effective in vivo. 36 We reasoned that lipid vehicles might enhance cellular uptake but at the same time decrease biological efficacy and might be more toxic. From this treatment, we found that further tumor growth over the next two weeks was reduced by the PTN-targeted ribozymes as compared to the inactive ribozymes that were used in the in vitro studies presented in Figure 5a . This reduction of subcutaneous tumor growth after only three intravenous applications was by 30% (P ¼ 0.018; ANOVA analysis).
In a second, more extensive in vivo study, PTNtargeted ribozymes were administered to mice every other day intraperitoneally for 18 days. In this study, Rz66 and Rz261 were administered in two different doses (1 and 5 mg/kg body weight, respectively). As shown in Figure 5b and c, the tumor size was reduced significantly by both ribozymes, with Rz66 being more effective than ribozyme Rz261. A reduction of tumor growth by 26 and 13%, respectively, was found for the 1 and 5 mg/kg dose of Rz261. For Rz66, a reduction by 33 and 27%, respectively, was found for the 1 and 5 mg/kg doses.
Serum levels of PTN. To test the efficacy of the ribozyme treatment, we monitored serum levels of PTN in the mice. Earlier studies had shown that serum levels of PTN in athymic nude mice are below detection and rise to easily detectable levels in parallel with the increasing size of PTN-producing subcutaneous tumors such as 1205LU melanoma. 37 We measured PTN serum concentrations in tumor-bearing mice at two subsequent time points, days 5 and 13 after initiation of the ribozyme treatment. We found that serum levels in control animals increased significantly between these two time points in parallel with the growing tumors. Ribozyme treatment inhibited this increase in a dose-dependent manner (Figure 5d ). Obviously, monitoring serum concentrations of PTN provides a direct read-out of the efficacy of the ribozyme treatment.
Metastases. The 1205LU melanoma form lung metastases within 10-12 weeks after tumor inoculation. 24 To allow for sufficient survival time of the animals, the subcutaneous, primary tumors were removed surgically after 20 and 24 days, and the treatment with ribozymes was continued for an additional 6 weeks. Macroscopic and microscopic analysis of the lungs of the animals at week 10 after inoculation of the tumor cells showed a trend toward a reduction in metastases by the ribozyme treatment (Table 1) . However, the differences were not statistically significant, as only three of eight untreated mice developed macroscopic or microscopic metastases.
Discussion
Ribozymes targeted against specific mRNA molecules have been shown to be a powerful tool to reduce the expression of eukaryotic genes (reviewed in Symons 38 and Pyle 39 ). In previous studies, we used this approach to target the growth factor PTN. We demonstrated a ribozyme-specific reduction of PTN expression, elucidating a rate-limiting role of PTN in various cell lines. These In the present studies, we used two approaches to assess the in vivo efficacy of PTN depletion in already established tumors: the tetracycline-regulated conditional gene expression system and synthetic ribozymes. We demonstrate that utilizing a tetracycline-regulated system, PTN mRNA levels were reduced in vitro in 1205LU melanoma cells. Northern analysis revealed reduction of PTN mRNA by 70%. Thus, this system can be used as a tool to switch on ribozyme expression in melanoma cells. When used in vivo in athymic nude mice, ribozymes switched on by the tetracycline-regulatory system reduced tumor growth significantly. As expected, the onset of effect was delayed for 5 days. This is probably due to the series of necessary preceding steps before an effect can be seen: after removal of the tetracycline pellets, the tetracycline levels drop, new tTA protein that does not form a complex with tetracycline is synthesized and the transcription of the PTN-targeted ribozymes is initiated. Decrease of PTN mRNA then leads to reduced synthesis of new protein, and degradation of existing protein according to its biological half-life eventually leads to reduction in tumor growth. This series of events is effective after a few days. Our data clearly indicate that ribozymes targeting PTN mRNA can reduce tumor growth of established tumors. The effect of about 30% reduction in tumor growth in vivo is less than the effect obtained from in vitro studies (70% reduction of PTN mRNA, see above) and in vivo studies with stably transfected ribozymes (65% reduction of tumor growth). 24 This is likely due to the fact that the tumors already had grown beyond several millimeters. There was no difference in growth discernible between the wild-type 1205LU tumor cells and tet-regulated tumor cells in the presence of tetracycline. This indicates that there were neither unspecific effects due to transfection nor leakiness of the promoter in vivo.
For a therapeutic approach, however, ribozymes will have to be delivered systemically and thus reach the tumor cells. As RNA is degraded by ubiquitous nucleases, we generated chemically modified, synthetic DNA/RNA chimeric ribozymes. Substitutions of DNA for RNA in the various stems of a hammerhead ribozyme but not in the catalytic center have been shown to be much more stable in serum without any loss of catalytic activity. 40 The in vitro PTN-targeting activity of synthetic Rz66 was shown in the dose-dependent reduction of colony formation of PTN-transfected SW-13 cells in soft agar. As controls, we used an active ribozyme with nonspecific targeting sequences and found that this drug did not affect colony formation. Also, a PTN-targeted ribozyme without catalytic activity did not affect colony formation significantly even at high concentrations. (Figure 5a) . Hence, antisense effects of the synthetic ribozymes do not seem to play a significant role in their efficacy, very similar to previous findings with ribozyme expression vectors. 25 In established tumors, it is difficult to deliver ribozymes to every tumor cell. Although stronger effects could be expected from local application into the tumor, we chose the more difficult but more relevant parenteral administration. When administered systemically (intravenously or intraperitoneally) to athymic nude mice bearing established melanoma xenografts, we showed in vivo biological efficacy of synthetic ribozymes as seen by tumor growth reduction in parallel with pharmacological efficacy reflected in the reduction of PTN serum levels in tumor-bearing animals. The extent of tumor growth reduction is about 30% for the combination of ribozymes Rz66 and Rz261 after intravenous administration and about 30% for ribozyme Rz66 (somewhat less for Rz261) after intraperitoneal administration. This is about the same effect as found in the study with the tetracyclineregulated ribozyme expression.
We found a distinct dose-response for the efficacy of the synthetic anti-PTN ribozymes reflected in the reduction of serum levels of the targeted growth factor, PTN. The highest dose of both ribozymes completely blocked the further increase in serum levels with growing tumors (Figure 5d ). Earlier studies in animals with 1205LU melanoma had shown a direct correlation between overall tumor load and PTN serum levels in mice. 37 This finding was also corroborated in patients with lung cancer where we observed a direct correlation between PTN serum levels and tumor load measured by CT scan. 41 However, the dose-response of anti-PTN ribozymes seen with the serum levels of PTN was not reflected as clearly in the tumor growth parameters (Figure 5c versus d) . We attribute this apparent discrepancy mostly to two factors: (i) the serum levels of PTN reflect the total mass of biologically active tumor cells, whereas the subcutaneous tumor size derived from the caliper readings of tumor diameters also includes stroma and skin. (ii) micrometastatic seedings of 1205LU melanoma occur relatively early after tumor cell inoculation. 24 These metastases contributed to elevated serum levels of PTN in mice when subcutaneous tumors were removed surgically. 37 From this, we propose that the PTN serum levels will likely be an excellent marker to monitor the efficacy of dose levels and dose intervals of PTN-targeted therapies.
PTN acts as a paracrine growth factor for the tumor stroma, and a small effect on local tumor growth can already be sufficient to reduce or inhibit the metastatic spread of the primary tumor. This would be of therapeutic significance in the treatment of metastatic Athymic nude mice were treated with synthetic ribozymes after tumor cell inoculation as described under 'Materials and methods'. After surgical removal of the primary tumors, the treatment was carried on for 10 weeks after tumor cell inoculation. The mice were killed and lungs were fixated in formalin, embedded in paraffin and three sections of different parts were stained with hematoxylin/ eosin and screened for formation of metastases.
Ribozyme targeting of PTN in tumors C Malerczyk et al malignancies. Previous studies showed that reduction of PTN in tumor cells had a significant inhibitory effect on tumor metastasis. 24 For that reason, the ribozyme treatment was continued after the primary tumors had been removed surgically. We investigated the formation of metastases 10 weeks after tumor cell inoculation. A nonsignificant trend toward less formation of metastases, compared to the control group, was observed (see Table  1 ). Very likely, the mice were killed too early for all control animals to develop lung metastases. 24 In conclusion, our results indicate that systemic administration of synthetic ribozymes is effective in reducing growth factor production in tumors and significantly inhibiting the growth of established tumors.
Materials and methods
Generation of constructs
The PTN-targeted ribozyme Rz66 was expressed under the control of the tTA/heptameric operator binding site and a cytomegalovirus (CMV) minimal promoter. The vector pTET/Rz66 was constructed as described earlier. 28 Briefly, the major portion of the luciferase gene and the simian virus 40 polyadenylation site in the pUHC13-3 plasmid 33 were replaced with the Rz66/bovine growth hormone polyadenylation fragment from the pRC/Rz66 expression vector. For cotransfection with the tTA expression vector, pUHD15-1 was used. 33 
Generation of synthetic ribozymes
Chemically synthesized ribozymes, targeting the PTN mRNA in the open-reading frame 66 and 261 nucleotides downstream of the translation initiation site (Rz66 and Rz261), as well as nonspecific random sequence ribozymes, were generated as described previously. 34 Briefly, automated RNA synthesis was carried out on an Applied Biosystems model 394 DNA/RNA synthesizer using the method of Scaringe et al, 42 modified according to Beigelman et al. 34 2 0 -O-methyl nucleotides were used to increase nuclease stability except for five ribonucleotides and two 2 0 -amino-uracils (see Figure 4 ). Ribozymes were protected from 5 0 -end degradation with phosphorothioate modifications and from 3 0 -end degradation with an inverted abasic nucleotide.
Cell lines, transfections and luciferase assay SW13 cells (from a human adrenal cell carcinoma) were obtained from American Type Culture Collection (Rockville, MD, USA) and cultured in improved MEM (Biofluids, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, MD, USA). Stable transfection with PTN expression vector was carried out as described before. 8 Human 1205LU melanoma cells (gift from M Herlyn, Wistar Institute, Philadelphia, PA, USA) were cultured in 75% keratinocyte-SMF medium, 25% Leibovitz's L-15 medium (Gibco BRL, Bethesda, MD, USA), supplemented with 5% FBS. A total of 2 Â 10 5 1205LU cells was grown in six-well plates to about 70% confluency and was transfected in serum-free medium (Optimem, Life Technologies, Gaithersburg, MD, USA) using 7 ml Lipofectamine (Life Technologies). pTET/Rz66 (0.8 mg DNA) was cotransfected with 1 mg tTA expression vector (pUHD15-1) and 0.6 mg pRC/CMV (Invitrogen, San Diego, CA, USA) to provide G418 resistance. After selection for stably transfected cells with G418 (Gibco BRL, Bethesda, MD, USA; 1000 mg/ml) in the presence of tetracycline (Sigma Chemical Co., St Louis, MO, USA; 1 mg/ml) for 10 weeks, cells were cultured with or without tetracycline (1 mg/ml) for 36 days and tested for reduction in PTN mRNA levels by Northern analysis. The usefulness of the tetracycline-regulatory system was evaluated for 1205LU cells as described earlier. 35 Briefly, for transient transfections 2 Â 10 5 1205LU cells were cotransfected with 1 mg tetO/CMV-driven luciferase reporter vector pUHC13-3 alone or with 1 mg tTA expression vector pUHD15-1 or with 1 mg pRC/LUC as a positive control using 7 ml Lipofectamine. Transfection medium was replaced with fresh medium in the absence or presence of tetracycline (1 mg/ml) for 48 h. The luciferase activity was determined after cell lysis as described. 43 
Growth assay
Inhibition of growth stimulating activity by the synthetic ribozymes was determined using a soft agar colonyforming assay of PTN-transfected SW-13 cells as described previously. 7, 44 Briefly, 20 000 cells were mixed with different amounts of ribozymes and melted agar (0.35 g/100 ml, final concentration; Bactoagar, Gibco BRL) in a total volume of 2.4 ml. A measure of 800 ml aliquots of this suspension was layered on top of a 1 ml bottom layer of 0.6 g of agar/100 ml of growth media in 35 mm dishes. Colonies of cells 460 mm were counted after 10 days of incubation using an image analyzer (Dynatech, Chantilly, VA, USA).
Northern analysis of stably transfected cells
Total RNA of stably transfected 1205LU/tetRz66 cells, treated with or without 1 mg/ml tetracycline for 36 days, was prepared with RNA-Stat60 (Tel-Test, Friendswood, TX, USA) according to the manufacturer's protocol. RNA (20 mg) was separated by electrophoresis in a 1% formaldehyde agarose gel and transferred to nylon membrane (0.22 mm, MSI, Westborough, MA, USA) by capillary action. The membrane was hybridized overnight with a 32 P-labeled (Rediprime, Amersham, Arlington Heights, IL, USA) fragment of human PTN openreading frame as described in Fang et al 8 in 50% formamide, 5 Â SSC, 0.1% (w/v) Ficoll, 0.1% (w/v) polyvinylpyrrolidone, 0.1% (w/v) BSA, 0.5% (w/v) sodium dodecyl sulfate (SDS) and 100 mg/ml denaturated salmon sperm DNA. The membrane was washed three times at 421C for 10 min in 2 Â SSC/0.1% SDS and once for 15 min with 0.1 Â SSC/0.1% SDS and was then exposed to Hyperfilm MP (Amersham Life Science, Buckinghamshire, UK) for 4-8 h at À801C. The membrane was stripped at 751C in 0.1 Â SSC/0.1% SDS for 60 min and reprobed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) plasmid to measure GAPDH mRNA. Signal intensities were quantified by phosphoimaging and normalized to GAPDH expression.
Tumor growth and metastasis in animals
In the study with tetracycline-regulated ribozymes, tetracycline pellets (Innovative Research of America, Sarasota, FL, USA), releasing about 0.7 mg tetracycline hydrochloride per day over a period of 60 days, were implanted subcutaneously in the back of athymic nude Ribozyme targeting of PTN in tumors C Malerczyk et al mice (female Ncr nu/nu; National Cancer Institute, Frederick, MD, USA; 5 mice/group). After 8 days, one million stable transfected melanoma cells 1205LU/ tetRz66 in 0.1 ml of growth medium were injected subcutaneously into two sites on the flanks of 10 mice. After 7 days, the tetracycline pellets were removed in five animals, and in five mice the pellets were kept. Additionally, five mice received one million wild-type 1205LU cells, and tetracycline pellets were removed after 7 days. Tumor sizes were estimated from the product of the perpendicular diameters of the tumors on a regular basis up to 26 days after tumor cell inoculation. In the study with intravenous administration of synthetic ribozymes, one million 1205LU melanoma cells in 0.1 ml of growth medium were injected subcutaneously into two sites on the flanks of 10 athymic nude mice. A mix of synthetic ribozymes Rz66 and Rz261 (ratio 1:2; 10 mg/kg) was administered to five mice intravenously through the tail vein twice a week. Ribozymes with random sequences in the hybridization area, administered at a slightly higher dose, served as a control (five mice). Tumor sizes were measured regularly and the tumors were resected surgically 20 days after tumor cell inoculation. In the study with intraperitoneal administration, 43 mice were subdivided into five groups of eight to nine animals (control group and four treatment groups). One million tumor cells (human 1205LU melanoma cells) were injected subcutaneously into two sites on the flanks on day 0. Synthetic ribozymes Rz66 or Rz261 were administered intraperitoneally every other day from days 4 to 20 in two different doses to the four treatment groups: Rz66, 1 mg/kg; Rz66, 5 mg/kg; Rz261; 1 mg/kg and Rz261, 5 mg/kg. Tumor sizes were estimated on a regular basis. Tumors were resected surgically on day 20, 48 h after ribozyme administration (one side) and on day 24 (96 h after the next dosage). Ribozyme administration was carried out three times a week up until 10 weeks after tumor cell inoculation. Lung metastasis was assessed by macroscopic inspection of the lungs 10 weeks after tumor cell inoculation. Microscopic inspection of three different sections per lung was carried out after paraffin embedding and hematoxylin/eosin staining.
Processing of blood samples
Venous blood samples (100-150 ml) for the PTN enzymelinked immunosorbent assay (ELISA) were obtained from anesthetized animals by puncture of the retroorbital sinus using a Pasteur pipette on days 5 and 13, 24 h after ribozyme administration. Blood was allowed to clot for about 6 h and was centrifuged at 8000 r.p.m. in a minicentrifuge. A measure of 50 ml of serum was diluted 1:1 with TBST (TBS, 0.5% Tween 20) and assayed for PTN using the ELISA sandwich assay described below.
ELISA for PTN
The PTN sandwich ELISA assay was performed as described previously. 37 Briefly, 96-well plates were coated overnight with 100 ml 4B7 mouse monoclonal anti-PTN antibody (1 mg/ml; gift from M Vigny, IN-SERM, Paris, France), washed and blocked with 200 ml blocking solution (TBST+1% BSA). The plates were then washed and incubated with 100 ml serum samples or standard samples (dilution series of 10 pg/ml to 20 ng/ ml PTN in blocking solution) for 1 h. The detection antibody (biotinylated, affinity-purified anti-human pleiotrophin goat IgG (R&D Systems, Minneapolis, MN, USA), 500 ng/ml) was added, followed by a 1-h incubation. The wells were then washed and incubated with 100 ml of streptavidin conjugated to alkaline phosphatase. Finally, the plates were washed and incubated with 100 ml p-nitrophenyl phosphate substrate (Pierce) in the dark for 4 h. Absorbance was measured using a microplate reader at 405 nm. Concentrations were determined by comparing the OD 405 with the standard curve.
Data analysis
For comparisons of tumor sizes between treatment groups, multivariate repeated measurements analysis of variance (ANOVA) was performed. Po0.05 was considered significant. For the tetracycline-regulated ribozyme study, repeated measurements ANOVA was also performed for the time points of different treatment (ie from the removal of tetracycline on day 7 on). For PTN serum concentrations, repeated measurements ANOVA was followed by Bonferroni's multiple comparison test. Occurrence of metastases was tested for significant differences with a w 2 test. The Prism program from Graphphad Software Inc. was used for the analysis.
